Literature DB >> 1348297

Genetic diagnosis of Gaucher's disease.

P K Mistry1, S J Smith, M Ali, C S Hatton, N McIntyre, T M Cox.   

Abstract

The inherited disorder Gaucher's disease can be caused by various mutations in the glucocerebrosidase gene. Some mutations may be associated with greater severity, and there is a need for methods of gene analysis that would facilitate screening and diagnosis. We have studied the molecular basis of Gaucher's disease in twelve unrelated patients of diverse ethnic origin by means of the amplification refractory mutation system (ARMS). Primers for the polymerase chain reaction were designed to discriminate between mutant and wild-type alleles of glucocerebrosidase and to allow separation from products of the related pseudogene. The nucleotide 1226 mutation (asparagine 370----serine) and 84GG (an insertional frameshift mutation) were found exclusively in five patients of Ashkenazi Jewish descent (7 and 2 of the 10 disease alleles, respectively). Two point mutations, at nucleotides 1448 (leucine 444----proline) and 1504 (arginine 463----cysteine), were found in 4 and 3 alleles, respectively; they were associated with rapidly progressive disease and neurological involvement in non-Jewish patients. The ARMS procedure for direct detection of common mutations in glucocerebrosidase will facilitate genetic counselling and screening programmes for individuals at risk of Gaucher's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348297     DOI: 10.1016/0140-6736(92)90928-v

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study.

Authors:  Rigoberto Gadelha Chaves; Janice Carneiro Coelho; Kristiane Michelin-Tirelli; Tibelle Freitas Maurício; Edineide de Freitas Maia Chaves; Paulo César de Almeida; Carlos Rômulo Filgueira Maurício; Geraldo Barroso Cavalcanti
Journal:  JIMD Rep       Date:  2011-06-22

2.  Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Authors:  Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

3.  Gaucher's disease in the United Kingdom: screening non-Jewish patients for the two common mutations.

Authors:  A J Walley; M L Barth; I Ellis; A H Fensom; A Harris
Journal:  J Med Genet       Date:  1993-04       Impact factor: 6.318

Review 4.  The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme.

Authors:  P K Mistry; T M Cox
Journal:  J Med Genet       Date:  1993-11       Impact factor: 6.318

5.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

6.  Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease.

Authors:  Nahid Tayebi; Barbara K Stubblefield; Joseph K Park; Eduard Orvisky; Jamie M Walker; Mary E LaMarca; Ellen Sidransky
Journal:  Am J Hum Genet       Date:  2003-02-13       Impact factor: 11.025

7.  Neonatal screening for hereditary fructose intolerance: frequency of the most common mutant aldolase B allele (A149P) in the British population.

Authors:  C L James; P Rellos; M Ali; A F Heeley; T M Cox
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

8.  Phenotype Expansion for Atypical Gaucher Disease Due to Homozygous Missense PSAP Variant in a Large Consanguineous Pakistani Family.

Authors:  Khurram Liaqat; Shabir Hussain; Anushree Acharya; Abdul Nasir; Thashi Bharadwaj; Muhammad Ansar; Sulman Basit; Isabelle Schrauwen; Wasim Ahmad; Suzanne M Leal
Journal:  Genes (Basel)       Date:  2022-04-09       Impact factor: 4.141

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.